DOI: 10.57760/sciencedb.12518
title: Analysis of adverse drug reactions induced by camrelizumab in our hospital and literature review
title: 我院卡瑞利珠单抗不良反应分析并文献复习

description: Objective: To analyze the situation and clinical characteristics of adverse drug reactions (ADRs) induced by camrelizumab, and provide references for clinical medication safety. Methods: Adverse drug reaction (ADR) of camrelizumab reported by the hospital and in the medical records from Jan. 2020 to Sep. 2022 were collected. Meanwhile, PubMed, Web of Science, CNKI, Vip and Wanfang databases were searched for ADRs induced by camrelizumab, and collected literatures were further analyzed statistically. Results: A total of 10 cases of ADR were reported in our hospital, including 9 male and 1 female. The patients’ ages ranged from 48 to 87 years, with an average age of (67.7±13.2) years. ADRs of camrelizumab frequently occurred within 120 days after medication. ADRs involved skin and adnexal, digestive system, cardiovascular system and endocrine system, etc. 8 patients got improved or recovered after discontinuation of medication and/or symptomatic support. Totally 65 papers of ADRs induced by camrelizumab were included, involving 72 patients(49 males and 23 females). The patients’ ages ranged from 32 to 87 years. Patients of 61 to 70 years showed the highest incidence (n=24, 33.3%). ADRs of camrelizumab frequently occurred within 90 days after medication. The main ADRs induced by camrelizumab were skin and adnexal lesions (n=27, 37.5%). 59 patients (81.9%) got improved or recovered after discontinuation of medication and/or symptomatic support. After the improvement of ADRs, 2 patients (2.8%) were retreated with camrelizumab and showed the same ADRs as before. There were also 5 patients (6.9%) who did not have ADR after ADRs had improved or recovered. Conclusion: The risk factors associated with ADR should be carefully evaluated in the clinical use of camrelizumab to improve patient medication safety.
description: Objective: To analyze the situation and clinical characteristics of adverse drug reactions (ADRs) induced by camrelizumab, and provide references for clinical medication safety. Methods: Adverse drug reaction (ADR) of camrelizumab reported by the hospital and in the medical records from Jan. 2020 to Sep. 2022 were collected. Meanwhile, PubMed, Web of Science, CNKI, Vip and Wanfang databases were searched for ADRs induced by camrelizumab, and collected literatures were further analyzed statistically. Results: A total of 10 cases of ADR were reported in our hospital, including 9 male and 1 female. The patients’ ages ranged from 48 to 87 years, with an average age of (67.7±13.2) years. ADRs of camrelizumab frequently occurred within 120 days after medication. ADRs involved skin and adnexal, digestive system, cardiovascular system and endocrine system, etc. 8 patients got improved or recovered after discontinuation of medication and/or symptomatic support. Totally 65 papers of ADRs induced by camrelizumab were included, involving 72 patients(49 males and 23 females). The patients’ ages ranged from 32 to 87 years. Patients of 61 to 70 years showed the highest incidence (n=24, 33.3%). ADRs of camrelizumab frequently occurred within 90 days after medication. The main ADRs induced by camrelizumab were skin and adnexal lesions (n=27, 37.5%). 59 patients (81.9%) got improved or recovered after discontinuation of medication and/or symptomatic support. After the improvement of ADRs, 2 patients (2.8%) were retreated with camrelizumab and showed the same ADRs as before. There were also 5 patients (6.9%) who did not have ADR after ADRs had improved or recovered. Conclusion: The risk factors associated with ADR should be carefully evaluated in the clinical use of camrelizumab to improve patient medication safety.